基于CT的影像组学特征优化II期错配修复完整结直肠癌的辅助化疗决策
回顾性纳入379例II期pMMR结直肠癌患者(验证队列125例),用XGBoost构建CT影像组学模型预测预后。验证队列中影像组学模型AUC为0.800、联合模型A为0.811,均优于临床模型A的0.576(均p<0.05);高风险组接受辅助化疗者总生存更长(p=0.015和p=0.008),低风险组无显著差异(均p>0.05)。
要点
- 验证队列中影像组学模型AUC为0.800,联合模型A为0.811,临床模型A为0.576。
- 影像组学模型或联合模型A判为低风险者总生存显著长于高风险者(均p<0.05)。
- 影像组学模型和联合模型A高风险组中,接受辅助化疗者总生存显著更长(p=0.015和p=0.008)。
核心结论
- 相比ESMO推荐的临床高风险因素,基于CT的影像组学模型预后预测性能更优,并可能依据风险分层优化II期pMMR结直肠癌的辅助化疗决策。
研究设计与样本
- 回顾性纳入379例II期pMMR结直肠癌患者(含验证队列125例),从分割CT体积提取特征并以XGBoost构建影像组学模型;临床模型A采用多因素logistic回归纳入ESMO推荐的临床因素;模型比较用DeLong检验,生存分析用Kaplan-Meier曲线和log-rank检验,并按风险分层做辅助化疗亚组分析。
诊断标准与关键数值
- 验证队列中影像组学模型AUC为0.800,联合模型A AUC为0.811,临床模型A AUC为0.576(前两者与临床模型A比较均p<0.05)。
临床应用与阅片要点
- 影像组学模型和联合模型A可将II期pMMR结直肠癌分为低风险与高风险,高风险组接受辅助化疗者总生存显著更长(p=0.015和p=0.008),低风险组接受与未接受辅助化疗者总生存无显著差异(均p>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To develop a CT-based radiomics model for predicting prognosis and optimizing adjuvant chemotherapy (ACT) decisions in stage II proficient mismatch repair (pMMR) colorectal cancer (CRC).
METHODS: We retrospectively enrolled 379 stage II pMMR CRC patients with distinctly good or poor outcomes, including 125 patients in the validation cohort. The radiomics model was developed using features extracted from segmented CT volumes by XGBoost. Clinical model A was constructed via multivariate logistic regression incorporating clinical factors recommended by the European Society of Medical Oncology (ESMO). Model performance was compared using the DeLong test. Survival analysis employed Kaplan-Meier curves and log-rank tests, and ACT subgroup analysis was performed according to risk stratification.
RESULTS: In the validation cohort, the radiomics model (AUC = 0.800) and combined model A (AUC = 0.811) outperformed clinical model A (AUC = 0.576; both p < 0.05). Patients stratified as low-risk by either the radiomics model or the combined model A exhibited significantly longer overall survival (OS) than high-risk patients in both training and validation cohorts (all p < 0.05). Within the high-risk groups identified by the radiomics model and the combined model A, patients receiving ACT showed significantly longer OS compared to non-recipients (p = 0.015 and p = 0.008, respectively), while no significant difference was observed in low-risk groups (both p > 0.05).
CONCLUSION: Compared to ESMO-recommended clinical high-risk factors, the CT-based radiomics model demonstrated superior prognostic prediction performance and could optimize ACT decisions based on risk stratification in stage II pMMR CRC.
引用
- Tang H, Xie Y, Li Q, et al. CT-based radiomics signature for optimizing adjuvant chemotherapy decisions in stage II colorectal cancer with proficient mismatch repair. Abdom Radiol (NY). 2026. PMID: 41860707. doi:10.1007/s00261-026-05456-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。